The selective inhibition of nuclear PKCζ restores the effectiveness of chemotherapeutic agents in chemoresistant cells.

Cell Cycle
Alessandro RimessiPaolo Pinton

Abstract

The atypical protein kinase C (PKC) isoform zeta (PKCζ) has been implicated in the intracellular transduction of mitogenic and apoptotic signals by acting on different signaling pathways. The key role of these processes in tumorigenesis suggests a possible involvement of PKCζ in this event. PKCζ is activated by cytotoxic treatments, inhibits apoptotic cell death and reduces the sensitivity of cancer cells to chemotherapeutic agents. Here, using pharmacological and DNA recombinant approaches, we show that oxidative stress triggers nuclear translocation of PKCζ and induces resistance to apoptotic agents. Accordingly, chemoresistant cells show accumulation of PKCζ within the nucleus, and a nuclear-targeted PKCζ transfected in tumor cells decreases sensitivity to apoptosis. We thus developed a novel recombinant protein capable of selectively inhibiting the nuclear fraction of PKCζ that restored the susceptibility to apoptosis in cells in which PKCζ was enriched in the nuclear fraction, including chemoresistant cells. These findings establish the importance of PKCζ as a possible target to increase the effectiveness of anticancer therapies and highlight potential sites of intervention.

References

Dec 1, 1989·Cancer Metastasis Reviews·C A O'Brian, N E Ward
Oct 1, 1987·Annals of Internal Medicine·C E CrossD Harman
Mar 3, 1993·Journal of the National Cancer Institute·G K SchwartzA P Albino
Apr 15, 1993·The Biochemical Journal·H Hug, T F Sarre
Jun 26, 1998·The Biochemical Journal·H Mellor, P J Parker
Jun 22, 1999·FEBS Letters·F Malisan, R Testi
Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·N KudoS Horinouchi
Aug 5, 2000·Free Radical Biology & Medicine·R Gopalakrishna, S Jaken
Jan 6, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·P M DangA Périanin
Dec 3, 2005·Cell Death and Differentiation·J MoscatM T Diaz-Meco
Apr 21, 2007·Methods in Cell Biology·Paolo PintonRosario Rizzuto
Jan 31, 2008·Cell Stress & Chaperones·Alessandro RimessiPaolo Pinton
Jun 5, 2008·Antioxidants & Redox Signaling·Dunyaporn TrachoothamPeng Huang
Dec 29, 2009·Frontiers in Bioscience (Landmark Edition)·Anna Malgorzata CzarneckaFrancesco Cappello
Feb 9, 2010·Antioxidants & Redox Signaling·Carlotta GiorgiPaolo Pinton
Jan 13, 2011·Cell Cycle·Fernando BenavidesMarcelo G Kazanietz
Mar 26, 2011·Science·Jocelyn Kaiser
Jul 7, 2011·Oncotarget·Melissa L SokoloskyJames A McCubrey

❮ Previous
Next ❯

Citations

Dec 18, 2013·Oncogene·R GargM G Kazanietz
Feb 18, 2016·Oxidative Medicine and Cellular Longevity·Aysegul CortLiudmila Korkina
Jan 7, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jing WuRui Yang
May 6, 2021·International Journal of Molecular Sciences·Ilaria GenoveseCarlotta Giorgi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.